IL2 and renal cell carcinoma: Following this observation, several clinical trials attempted to carry out in vivo stimulations of autologous Vδ2 T with ABPs (ABP pamidronate and zoledronate) and synthetic PhAg analogs (BrHPP and 2M3B1PP) alone or in combination with IL-2 in patients with multiple myeloma (MM), non-Hodgkin lymphoma (NHL), follicular lymphoma, AML, prostate cancer, renal cell carcinoma (RCC), CRC, breast cancer, melanoma, and neuroblastoma [88,89,90,91,92,93,94,95].